Q-omics provides the consensus-scored PPP2R5D profile across patient tissues and cancer cell-line models. PPP2R5D expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PPP2R5D is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, PPP2R5D protein abundance shows 23,831 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where PPP2R5D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP2R5D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP2R5D survival associations across molecular data types. PPP2R5D RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP2R5D RNA expression–survival associations across cancer types. High PPP2R5D expression shows unfavorable associations in ACC, KICH, LIHC, SARC and MESO, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PPP2R5D RNA expression.
This table summarizes PPP2R5D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PPP2R5D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP2R5D shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, LUSC and COAD. The HNSC box plot shows higher PPP2R5D RNA expression in tumor versus normal tissue (log2 FC = +0.771, t-test p < 0.001).
This table shows molecular features associated with PPP2R5D in patient tissues and cancer cell lines. In patient samples, PPP2R5D shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PPP2R5D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
